Here's what research had to say about Psilocybin Therapy in 2022
Most cited journal articles on Psilocybin Therapy published in 2022
Psilocybin therapy refers to the use of psilocybin, a psychoactive compound found in certain species of mushrooms, in a therapeutic setting to treat mental health conditions such as depression, anxiety, PTSD, and addiction.
Research on psilocybin therapy has shown that it has potential therapeutic benefits, but it is still in the early stages of research. Studies have found that psilocybin therapy can lead to significant reductions in symptoms of depression and anxiety, as well as improvements in measures of well-being and quality of life.
Research has also shown that psilocybin therapy can be effective in treating treatment-resistant conditions such as depression and PTSD and that it can help people to quit smoking, alcohol, and other substance abuse.
Research has also shown that the therapeutic effects of psilocybin are likely related to its ability to promote neuroplasticity, which is the ability of the brain to change and adapt in response to new experiences. Psilocybin therapy has also been found to increase brain-derived neurotrophic factor (BDNF) which is a protein that helps to support the growth and survival of neurons.
Research is ongoing to understand the mechanisms by which psilocybin therapy works, as well as the best ways to administer and regulate it for therapeutic use. Researchers are also working to understand the long-term effects of psilocybin therapy and how to minimize any potential risks.
It is worth noting that psilocybin is currently a Schedule I controlled substance, meaning it is illegal to possess, use, or distribute it in the United States. However, some cities and states have decriminalized the possession of small amounts of psilocybin, and some research is being done under the "compassionate use" exemption.